Invitrogen expects to continue its aggressive acquisition strategy through the remainder of the year, but it is possible after a string of relatively small purchases that the firm may be ready to add a "transforming" piece to its business, CEO Greg Lucier suggested during a webcast last week.

Lucier was one of several members of Invitrogen's management to address attendees of the company's 2005 investor meeting at its headquarters in Carlsbad, Calif.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.